S2 Table: Baseline Immune Activation of 3TC/FTC Monotherapy Arm by Immunologic Deterioration

|   | Experienced Immunologic Deterioration (Median (IQR)) |
| --- | --- |
|  |  | No(N=4) | Yes(N=4) | P-Value\* |
| (CD3+/CD4+) CD38+ HLA-DR+ [CD4 activated, CD4A] |  | 4.0 (2.9, 6.1) | 5.9 (3.8, 11.0) | 0.67 |
|  |
| (CD3+/CD4+) CD95+ [CD4 Fas receptor, CD4F] |  | 31.7 (24.7, 48.4) | 35.4 (25.8, 49.3) | 0.89 |
|  |
| (CD3+/CD8+) CD38+ HLA-DR+ [CD8 activated, CD8A] |  | 36.1 (33.2, 36.4) | 31.6 (19.5, 47.3) | >0.99 |
|  |
| (CD3+/CD8+) CD95+ [CD8 Fas receptor, CD8F] |  | 67.1 (14.8, 71.7) | 36.1 (18.8, 45.8) | 0.38 |
|  |
| (CD3+/CD4+) CD27+CD45RO- CD95- [CD4 naïve, CD4N] |  | 56.6 (45.2, 66.6) | 45.3 (29.3, 61.0) | 0.47 |
|  |
| (CD3+/CD8+) CD27+CD45RO- CD95- [CD8 naïve, CD8N] |  | 23.7 (18.7, 76.4) | 42.9 (21.4, 59.1) | >0.99 |
|  |
| (CD3+/CD4+) CD31+ CD27+ CD45RO- CD95- [Recent thymic emigrants, RTE] |  | 39.4 (32.8, 55.0) | 34.2 (23.9, 53.0) | 0.47 |
|  |
| \*Wilcoxon Test |